tv.qiagenbioinformatics.com marketingbiox@qiagen.com https://tv.qiagenbioinformatics.com Watch tutorials, interviews and much more on our web based TV channel! en-us Visualplatform http://blogs.law.harvard.edu/tech/rss tv.qiagenbioinformatics.com CLC bio TV Watch tutorials, interviews and much more on our web based TV channel! clc bio tv, bioinformatics, genomics, research episodic no https://tv.qiagenbioinformatics.com/files/rv0.0/sitelogo.gif https://tv.qiagenbioinformatics.com http://tv.qiagenbioinformatics.com/photo/103653025/how-to-accelerate-your-clinical <p>As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.<br /> <br /> <br /> <br /> In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.<br /> <br /> <br /> <br /> Topics covered in this webinar:<br /> - QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.<br /> - Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.<br /> - How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103653025/how-to-accelerate-your-clinical"><img src="http://tv.qiagenbioinformatics.com/64968575/103653025/675290b7aa7d16b00cc46872b131d755/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/103653025 Sat, 17 Aug 2024 22:22:39 GMT How to accelerate your clinical reporting workflow for high-throughput... As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner. In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information. Topics covered in this webinar: - QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner. - Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up. - How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click. As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match... tv.qiagenbioinformatics.com 50:45 <p>As the demand for personalized cancer treatment grows, clinical diagnostic labs are facing unprecedented pressure to scale-up, increase test throughput, reduce turnaround times, and deliver comprehensive, oncologist-ready reports that match patients to the most appropriate therapies and clinical trials, in a time-efficient manner.<br /> <br /> <br /> <br /> In this webinar, learn how QIAGEN Clinical Insight (QCI) Interpret for Oncology, the world’s leading variant interpretation and reporting software, can help your lab accelerate your clinical reporting workflow for high-throughput precision oncology NGS testing. The webinar will demonstrate the capabilities and features of QCI Interpret for Oncology through an example workflow for comprehensive genomic profiling. Key highlights include the software’s capability to expedite variant interpretation, dynamically compute pathogenicity and actionability based on the ACMG and AMP/ASCO/CAP guidelines for every variant in over 30,000 cancer types and subtypes with full transparency. Additionally learn how to leverage over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries to build customizable, oncologist-ready reports with up-to-date gene, variant, diagnostic, prognostic and therapeutic information.<br /> <br /> <br /> <br /> Topics covered in this webinar:<br /> - QCI Interpret for Oncology’s new performance and scalability enhancements, including bulk variant assessment, flagging of co-occurring variants, and a somatic reporting policy that allows users to set pathogenicity in a phenotype-agnostic manner.<br /> - Learn how the panel- and sequencer-agnostic software can facilitate true scalability by rendering efficient test and process management capabilities, quick identification and comparison of tests from a patient for follow-up.<br /> - How the software’s underlying knowledge base combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered) to identify all the literature, treatments, and clinical trials relevant to a patient’s tumor type with just one-click.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103653025/how-to-accelerate-your-clinical"><img src="http://tv.qiagenbioinformatics.com/64968575/103653025/675290b7aa7d16b00cc46872b131d755/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> oncology qci interpret http://tv.qiagenbioinformatics.com/photo/103037588/benefits-of-integrating-targeted <p>Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile.</p> <p>To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes.</p> <p>In this webinar, attendees will:<br /> - Understand the clinical utility of custom-designed NGS panels for accurate tumour diagnosis<br /> - Learn about the design and application of these NGS panels<br /> - Gain insights into the cost-effectiveness and high sensitivity of NGS panels in improving sample throughput<br /> <br /> <br /> Category: QCI Interpret for Oncology, Sample to Insight</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103037588/benefits-of-integrating-targeted"><img src="http://tv.qiagenbioinformatics.com/64968558/103037588/d8cd6e0b62a97b149226f46fb7bf8873/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/103037588 Thu, 18 Jul 2024 16:20:54 GMT Benefits of integrating targeted next-generation sequencing (NGS) panels into... Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile. To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes. In this webinar, attendees will: - Understand the clinical utility of custom-designed NGS panels for accurate tumour diagnosis - Learn about the design and application of these NGS panels - Gain insights into the cost-effectiveness and high sensitivity of NGS panels in improving sample throughput Category: QCI Interpret for Oncology, Sample to Insight Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the... tv.qiagenbioinformatics.com 01:01:57 <p>Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in clinical settings for accurate tumor profiling and the identification of essential molecular aberrations for personalized therapies. By focusing only on a subset of genes, targeted NGS is not only a cost-effective solution, but can rapidly deliver insights into a tumor molecular profile.</p> <p>To address this challenge, a clinical research team led by Dr. Michela Bulfoni at the Istituto di Anatomia Patologica designed custom NGS panels, named “Glioma” and “Routine Diagnostics”, targeting single nucleotide variations, insertions/deletions, fusions, and copy number variations of tumor-associated essential genes.</p> <p>In this webinar, attendees will:<br /> - Understand the clinical utility of custom-designed NGS panels for accurate tumour diagnosis<br /> - Learn about the design and application of these NGS panels<br /> - Gain insights into the cost-effectiveness and high sensitivity of NGS panels in improving sample throughput<br /> <br /> <br /> Category: QCI Interpret for Oncology, Sample to Insight</p><p><a href="http://tv.qiagenbioinformatics.com/photo/103037588/benefits-of-integrating-targeted"><img src="http://tv.qiagenbioinformatics.com/64968558/103037588/d8cd6e0b62a97b149226f46fb7bf8873/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> qci interpret QCI Interpret for Oncology Sample to Insight http://tv.qiagenbioinformatics.com/photo/102108300/how-decentralized-and-small-labs <p>Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.</p> <p>To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.</p> <p>In this webinar, attendees will learn how QCI Secondary Analysis:<br /> <br /> . Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.<br /> . Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.<br /> . Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/102108300/how-decentralized-and-small-labs"><img src="http://tv.qiagenbioinformatics.com/64968560/102108300/2b796ab5541b12a24e2d75eb8bf84bf7/standard/download-8-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/102108300 Fri, 14 Jun 2024 23:53:55 GMT How decentralized and small labs can adopt high-throughput NGS analysis with... Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure. To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications. In this webinar, attendees will learn how QCI Secondary Analysis: . Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment. . Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements. . Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time. Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small... tv.qiagenbioinformatics.com 32:39 <p>Next-generation sequencing (NGS) has rapidly gained popularity as a diagnostic testing approach due to its unparalleled ability to comprehensively analyze genetic information with high throughput and precision. However, decentralized and small labs face significant hurdles when it comes to adopting NGS testing. From high upfront costs associated with acquiring the necessary equipment, to the complexity of bioinformatics tools and compliance management that require specialized expertise in data analysis and data security, adopting NGS poses challenges for labs with limited staff and infrastructure.</p> <p>To empower small and decentralized labs to easily adopt NGS testing, QIAGEN has launched a new secondary analysis solution for oncology and inherited disease applications that enables high-throughput secondary analysis for use with any clinical NGS data. In this webinar, learn about QCI Secondary Analysis, an agnostic, cloud-based software-as-a-service (SaaS) solution that seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly scalable and customizable Sample to Insight workflows for oncology and inherited disease applications.</p> <p>In this webinar, attendees will learn how QCI Secondary Analysis:<br /> <br /> . Streamlines analysis from a range of assay types, enabling labs to process more sequencing data without extensive time and resource investment.<br /> . Ensures the highest degree of isolation and data protection, including compliance with ISO 27001, General Data Protect Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPPA) requirements.<br /> . Directly connects to QCI Interpret for an integrated and automated FASTQ-to-report workflow with limited hands-on time.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/102108300/how-decentralized-and-small-labs"><img src="http://tv.qiagenbioinformatics.com/64968560/102108300/2b796ab5541b12a24e2d75eb8bf84bf7/standard/download-8-thumbnail.jpg" width="75" height=""/></a></p> clinical NGS Secondary Analysis NGS webinar QCI Hereditary QCI Interpret webinar http://tv.qiagenbioinformatics.com/photo/101716342/expert-panel-mitigating-variability <p>Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented amount of genomic information is uncovered, there is an industry-wide issue of standardization: a high degree of variability in variant interpretation currently exists across laboratories.</p> <p>Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this previously aired live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories.</p> <p>Topics of discussion include:</p> <p>Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories.<br /> Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability.<br /> The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/101716342/expert-panel-mitigating-variability"><img src="http://tv.qiagenbioinformatics.com/64968558/101716342/268cadcd383cd2bd3c286fdfcf06a545/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/101716342 Thu, 06 Jun 2024 19:25:52 GMT Expert panel: Mitigating variability in somatic variant interpretation Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented amount of genomic information is uncovered, there is an industry-wide issue of standardization: a high degree of variability in variant interpretation currently exists across laboratories. Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this previously aired live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories. Topics of discussion include: Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories. Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability. The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications. Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented... tv.qiagenbioinformatics.com 01:00:23 <p>Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. But as NGS is increasingly used in precision oncology and an unprecedented amount of genomic information is uncovered, there is an industry-wide issue of standardization: a high degree of variability in variant interpretation currently exists across laboratories.</p> <p>Inconsistencies in variant interpretation among laboratories can create confusion for clinicians and their patients, leaving them unable to confidently use genetic information to manage healthcare decisions. In this previously aired live panel discussion, experts in NGS testing and clinical informatics explore the issues surrounding the standardization of variant interpretation and consider how interpretation guidelines and clinical decision support (CDS) software can help to mitigate variability between laboratories.</p> <p>Topics of discussion include:</p> <p>Findings of a peer-reviewed study comparing the accuracy and consistency of variant assessments from commercial CDS software to the internal variant interpretation methods of eight laboratories.<br /> Causes of inter-laboratory inconsistency in variant interpretation and how to mitigate variability.<br /> The benefits of having an up-to-date, high-quality knowledge base to produce consistent, evidence-based clinical classifications.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/101716342/expert-panel-mitigating-variability"><img src="http://tv.qiagenbioinformatics.com/64968558/101716342/268cadcd383cd2bd3c286fdfcf06a545/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> oncology qci interpret http://tv.qiagenbioinformatics.com/photo/96154284/agilent-alissa-to-qci-interpret-how <p>In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including:</p> <p>Content quality for clinical reporting<br /> Flexibility to adapt current workflows to a new platform<br /> Retaining historical content and comments<br /> Ease of personnel training</p> <p>In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition to QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/96154284/agilent-alissa-to-qci-interpret-how"><img src="http://tv.qiagenbioinformatics.com/64968571/96154284/77267060f7cbc751392aebf88d143173/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/96154284 Tue, 26 Mar 2024 17:54:22 GMT Agilent Alissa to QCI Interpret: How can your lab reduce the stress and... In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including: Content quality for clinical reporting Flexibility to adapt current workflows to a new platform Retaining historical content and comments Ease of personnel training In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition to QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide. In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software... tv.qiagenbioinformatics.com 38:37 <p>In 2023, Agilent announced the discontinuation of their Alissa Interpret clinical informatics platform by the end of 2024. As a result, many of their current customers need to transition to a new variant interpretation and reporting software within a tight timeframe. However, when evaluating new interpretation solutions, clinical labs must consider a variety of factors, including:</p> <p>Content quality for clinical reporting<br /> Flexibility to adapt current workflows to a new platform<br /> Retaining historical content and comments<br /> Ease of personnel training</p> <p>In this webinar, learn about QCI Interpret, a panel- and sequencer-agnostic clinical informatics platform for NGS variant interpretation and reporting of germline and somatic tests. Our experts will address the concerns of current Alissa users and discuss what sets QCI Interpret apart from other interpretation solutions. In addition, we will show you how seamless it is to transition to QCI Interpret, as well as provide a live demonstration of the industry-leading and reliable software that has been used to analyze and interpret more than 3.5 million patient test cases worldwide.</p><p><a href="http://tv.qiagenbioinformatics.com/photo/96154284/agilent-alissa-to-qci-interpret-how"><img src="http://tv.qiagenbioinformatics.com/64968571/96154284/77267060f7cbc751392aebf88d143173/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> agilent qci interpret http://tv.qiagenbioinformatics.com/photo/90542105/how-to-scale-up-comprehensive <p>As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time. <p>In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:</p> <p>Navigate from VCF to final report with speed, precision, and confidence;<br> Easily issue report addendums without the need for re-running a VCF;<br> Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;<br> Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/90542105/how-to-scale-up-comprehensive"><img src="http://tv.qiagenbioinformatics.com/64968580/90542105/4ca578ccb90ac667eb6431046879a999/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/90542105 Fri, 10 Nov 2023 13:58:00 GMT How to scale-up comprehensive genomic profiling and deliver confident variant... As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time. In this webinar, attendees will learn how QCI Interpret for Oncology enables you to: Navigate from VCF to final report with speed, precision, and confidence; Easily issue report addendums without the need for re-running a VCF; Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting; Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click. As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI)... tv.qiagenbioinformatics.com 01:00:00 <p>As gene panels increase in size, comprehensive genomic profiling and variant interpretation becomes more complex and time-consuming, which places tremendous burden on labs needing to scale and grow case volume. QIAGEN Clinical Insight (QCI) Interpret for Oncology is a clinical decision support platform powered by augmented molecular intelligence that enables rapid, evidence-powered comprehensive genomic profiling at scale. QCI Interpret for Oncology is supported by the world’s most comprehensive, manually curated knowledge base and dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with transparency. Users also get access to over 500,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapeutic information and clinical trial recommendations. With its latest release, QCI Interpret for Oncology adds several new capabilities that further enhances the platform’s scalability and flexibility, and enables users to significantly reduce variant research and review time. <p>In this webinar, attendees will learn how QCI Interpret for Oncology enables you to:</p> <p>Navigate from VCF to final report with speed, precision, and confidence;<br> Easily issue report addendums without the need for re-running a VCF;<br> Streamline structural variant filtering based on user set thresholds and hence reduce the time and effort needed to eliminate noise and identify truly relevant variants for reporting;<br> Utilize built-in AI capabilities to identify all the literature, case reports, drug therapies, and clinical studies relevant to a patient’s tumor type with just one-click.</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/90542105/how-to-scale-up-comprehensive"><img src="http://tv.qiagenbioinformatics.com/64968580/90542105/4ca578ccb90ac667eb6431046879a999/standard/download-7-thumbnail.jpg" width="75" height=""/></a></p> oncology qci interpret SWAN http://tv.qiagenbioinformatics.com/photo/84318668/comprehensive-molecular-tumor <p>Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME). <p>Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports.&nbsp; CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.</p> <p>In this webinar, viewers will:</p> <p>Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events<br> Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies<br> Be eligible for a complimentary QCI Interpret demo and sample report</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/84318668/comprehensive-molecular-tumor"><img src="http://tv.qiagenbioinformatics.com/64968555/84318668/87d4b9e71d8fcdce2b42b8b37442fb07/standard/download-6-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/84318668 Thu, 09 Mar 2023 16:16:33 GMT Comprehensive Molecular Tumor Analysis with Alacris Theranostics Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME). Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports. CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin. In this webinar, viewers will: Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies Be eligible for a complimentary QCI Interpret demo and sample report Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene... tv.qiagenbioinformatics.com 01:01:33 <p>Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions. Integrating gene expression analysis in personalized oncology provides an additional level of insight. These analyses include evaluating expressed mutations and drug targets, novel gene fusions, clinically relevant signatures, and the tumor immune microenvironment (TME). <p>Alacris Theranostics developed the Comprehensive Molecular Tumor Analysis (CMTA), a NGS-based tumor diagnostic test. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq). The test deploys as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation reports.&nbsp; CMTA is a tumor-agnostic test that displays a unique molecular view of each sample. CMTA is a useful approach for refractory cancers with complex patterns or tumors of unknown origin.</p> <p>In this webinar, viewers will:</p> <p>Learn about the strategy implemented in Alacris’ bioinformatics pipeline to identify cancer-relevant somatic events<br> Learn how Alacris uses QCI Interpret for Oncology to annotate variants and identify potential therapies<br> Be eligible for a complimentary QCI Interpret demo and sample report</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/84318668/comprehensive-molecular-tumor"><img src="http://tv.qiagenbioinformatics.com/64968555/84318668/87d4b9e71d8fcdce2b42b8b37442fb07/standard/download-6-thumbnail.jpg" width="75" height=""/></a></p> oncology qci interpret http://tv.qiagenbioinformatics.com/photo/81422637/emerging-clinical-trends-in-1 <p>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing <p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p> <p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p> <p>An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing.</p> <p>Attendees will gain:</p> <p>Insight into how leading laboratories address bottlenecks in their NGS data pipelines<br> Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants<br> An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/81422637/emerging-clinical-trends-in-1"><img src="http://tv.qiagenbioinformatics.com/64968569/81422637/5bd9dcc53e86885298fe0b0f683b2b65/standard/download-22-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/81422637 Thu, 17 Nov 2022 19:00:47 GMT Emerging clinical trends in germline NGS testing: Expert Panel Discussion in USA Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation. Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers. An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing. Attendees will gain: Insight into how leading laboratories address bottlenecks in their NGS data pipelines Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses,... tv.qiagenbioinformatics.com 01:22:05 <p>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing <p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p> <p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p> <p>An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing.</p> <p>Attendees will gain:</p> <p>Insight into how leading laboratories address bottlenecks in their NGS data pipelines<br> Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants<br> An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation</p></p><p><a href="http://tv.qiagenbioinformatics.com/photo/81422637/emerging-clinical-trends-in-1"><img src="http://tv.qiagenbioinformatics.com/64968569/81422637/5bd9dcc53e86885298fe0b0f683b2b65/standard/download-22-thumbnail.jpg" width="75" height=""/></a></p> hereditary hereditary ngs summit qci interpret http://tv.qiagenbioinformatics.com/photo/81412632/emerging-clinical-trends-in <p><p><b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><b> </b><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p> <p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p> <p>An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing.</p> <p>Attendees will gain:</p> <ul><li>Insight into how leading laboratories address bottlenecks in their NGS data pipelines</li><li> Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants</li><li> An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation</li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/81412632/emerging-clinical-trends-in"><img src="http://tv.qiagenbioinformatics.com/64968577/81412632/7f32e5b3f1a7b21070a98391d15d4557/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/81412632 Thu, 17 Nov 2022 07:03:21 GMT Emerging clinical trends in germline NGS testing: Expert Panel Discussion in... Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation. Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers. An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing. Attendees will gain: Insight into how leading laboratories address bottlenecks in their NGS data pipelines Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses,... tv.qiagenbioinformatics.com 01:10:25 <p><p><b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><b> </b><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p> <p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p> <p>An expert panel of leading medical geneticists, variant scientists and bioinformaticians will discuss emerging scientific and clinical trends in germline NGS testing.</p> <p>Attendees will gain:</p> <ul><li>Insight into how leading laboratories address bottlenecks in their NGS data pipelines</li><li> Tips on how to solve process inefficiencies of critical workflow components, including variant curation and interpreting rare or novel variants</li><li> An outlook on how germline NGS analysis and interpretation will change in the next 5 years and how to remain at the forefront of innovation</li></ul></p><p><a href="http://tv.qiagenbioinformatics.com/photo/81412632/emerging-clinical-trends-in"><img src="http://tv.qiagenbioinformatics.com/64968577/81412632/7f32e5b3f1a7b21070a98391d15d4557/standard/download-13-thumbnail.jpg" width="75" height=""/></a></p> hereditary hereditary ngs summit qci interpret http://tv.qiagenbioinformatics.com/photo/79848955/next-gen-software-workflow-for-1 <p><p><b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p><p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p><p>Part I: Thursday, October 13, 2022&nbsp;</p><p>An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.</p><p>Attendees will learn:</p><ul><li>How to simplify NGS secondary analysis workflows to 5 steps</li><li>How to solve every hereditary disorder case for all types of mutations</li><li>How to address current challenges in germline and exome analytics&nbsp;</li></ul>Click <a href="https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret/">here</a> to learn more.<br></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79848955/next-gen-software-workflow-for-1"><img src="http://tv.qiagenbioinformatics.com/64968561/79848955/7076286132fd906f856326e5d50e4db5/standard/download-20-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/79848955 Tue, 18 Oct 2022 15:18:39 GMT Next-gen software workflow for germline testing: QIAGEN Expert talks in Europe Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline TestingOver the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.Part I: Thursday, October 13, 2022An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.Attendees will learn:How to simplify NGS secondary analysis workflows to 5 stepsHow to solve every hereditary disorder case for all types of mutationsHow to address current challenges in germline and exome analyticsClick here to learn more. Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline TestingOver the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses,... tv.qiagenbioinformatics.com 01:50:33 <p><p><b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p><p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.</p><p>Part I: Thursday, October 13, 2022&nbsp;</p><p>An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.</p><p>Attendees will learn:</p><ul><li>How to simplify NGS secondary analysis workflows to 5 steps</li><li>How to solve every hereditary disorder case for all types of mutations</li><li>How to address current challenges in germline and exome analytics&nbsp;</li></ul>Click <a href="https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret/">here</a> to learn more.<br></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79848955/next-gen-software-workflow-for-1"><img src="http://tv.qiagenbioinformatics.com/64968561/79848955/7076286132fd906f856326e5d50e4db5/standard/download-20-thumbnail.jpg" width="75" height=""/></a></p> hereditary hereditary ngs summit qci interpret http://tv.qiagenbioinformatics.com/photo/79848961/next-gen-software-workflow-for <p><p> <b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p><p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.&nbsp;&nbsp;</p><p>Part I: Thursday, October 13, 2022&nbsp;</p><p>An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.</p><p>Attendees will learn:</p><ul><li>How to simplify NGS secondary analysis workflows to 5 steps</li><li>How to solve every hereditary disorder case for all types of mutations</li><li>How to address current challenges in germline and exome analytics&nbsp;</li></ul>Click <a href="https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret/">here</a> to learn more.<br></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79848961/next-gen-software-workflow-for"><img src="http://tv.qiagenbioinformatics.com/64968560/79848961/844065c6f09af7737f2bd428973f3272/standard/download-9-thumbnail.jpg" width="75" height=""/></a></p> http://tv.qiagenbioinformatics.com/photo/79848961 Tue, 18 Oct 2022 15:00:31 GMT Next-gen software workflow for germline testing: QIAGEN Expert talks in USA Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline TestingOver the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.Part I: Thursday, October 13, 2022An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.Attendees will learn:How to simplify NGS secondary analysis workflows to 5 stepsHow to solve every hereditary disorder case for all types of mutationsHow to address current challenges in germline and exome analyticsClick here to learn more. Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline TestingOver the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses,... tv.qiagenbioinformatics.com 02:06:35 <p><p> <b>Hereditary NGS Clinical Summit Series: Build a Next-Gen Software Workflow for Germline Testing</b></p><p>Over the past two decades, huge advancements in sequencing technology have transformed our understanding of human genetics, leading to faster diagnoses, earlier prevention, and better treatments. But as more and more people have their genomes sequenced, outpacing our ability to analyze and interpret the generated data, we must embrace new tools, technologies, and strategies to realize the full value of genomic innovation.</p><p>Advance your lab’s germline testing capabilities by learning how to build a next-gen software workflow, as part of the Hereditary NGS Clinical Summit Series, a two-part, free-to-attend virtual event for variant scientists, bioinformaticians, clinical geneticists, and lab managers.&nbsp;&nbsp;</p><p>Part I: Thursday, October 13, 2022&nbsp;</p><p>An informative scientific and clinical segment focusing on how to streamline and scale components of the NGS analytical workflow.</p><p>Attendees will learn:</p><ul><li>How to simplify NGS secondary analysis workflows to 5 steps</li><li>How to solve every hereditary disorder case for all types of mutations</li><li>How to address current challenges in germline and exome analytics&nbsp;</li></ul>Click <a href="https://digitalinsights.qiagen.com/products-overview/clinical-insights-portfolio/qiagen-clinical-insight/qci-interpret/">here</a> to learn more.<br></p><p><a href="http://tv.qiagenbioinformatics.com/photo/79848961/next-gen-software-workflow-for"><img src="http://tv.qiagenbioinformatics.com/64968560/79848961/844065c6f09af7737f2bd428973f3272/standard/download-9-thumbnail.jpg" width="75" height=""/></a></p> hereditary hereditary ngs summit qci interpret